CND Receives Grant from The Michael J. Fox Foundation to Study Quantification of Cutaneous Phosphorylated Alpha-Synuclein (P-SYN) in People with Parkinson’s Disease. See the release
DIAGNOSTIC INSIGHTS FOR LIFE®
CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.
DIAGNOSTIC INSIGHTS FOR LIFE™
CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.
Introducing the Syn-One Test® from CND Life Sciences
The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.
CLIA-Certified and CAP-Accredited Pathology Lab
Dedication to Science, Research, Quality, and Reliability
Patient-Focused Mission
High Accuracy: >95% Sensitivity and Specificity
Clarity and Confidence of Syn-One
Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.
Our Commitment to Patients
We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.
Learn more about what drives us.